Johnson Financial Group, Inc. Cellectar Biosciences, Inc. Transaction History

Johnson Financial Group, Inc.

  • $2.06 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021
BUY
$11.8 - $18.2 $11,800 - $18,200
1,000 Added 22.22%
5,500 $7,000
Q1 2021

May 14, 2021
BUY
$15.2 - $25.0 $68,400 - $112,500
4,500 New
4,500 $7,000

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $13M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Johnson Financial Group, Inc. Portfolio

Follow Johnson Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Johnson Financial Group, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email